|
Bone marrow
|
Clinical and pre-clinical [7],[38],[45],[47],[48],[51],[53],[59],[60],[65],[66],[68],[69],[71]-[73],[76]-[78],[80]-[85],[88]-[91],[97]
|
Most rigorous investigation and strongest supporting evidence
|
Propensity to form osseous tissue (could be beneficial for osseous regeneration in osteochondral lesions)
|
|
Ease of collection by needle
|
|
Long-term safety reported
|
|
Peripheral blood
|
Clinical and pre-clinical [29],[61],[98]
|
Ease of collection by needle
|
Paucity of literature comparing this source to others
|
|
Synovial tissue
|
Pre-clinical [50],[52]-[54],[56],[62],[64],[67],[70]
|
Greatest chondrogenic capacity noted based on in vitro study
|
Clinical assessment is lacking
|
|
Periosteum
|
Pre-clinical [7],[56]
|
Equivalent chondrogenic capacity to bone marrow
|
Propensity to form osseous tissue
|
|
Clinical assessment is lacking
|
|
Adipose tissue
|
Pre-clinical [46],[49],[56]
|
Abundance of tissue
|
Reduced chondrogenic capacity
|
|
Widespread anatomic availability
|
Clinical assessment is lacking
|
